All Articles

Amid record travel demand and new jet delays, lessors like Willis Lease are finding value in older aircraft, providing a critical bridge for expanding airlines.

CivStart launches Clarity, a free AI decision tool for local governments, offering a strategic alternative to costly consultants and bureaucratic delays.

A new virtual exhibit showcases public art from all 50 states, democratizing culture for America's 250th. What does this mean for the art industry?

As AI agent pilots face a 95% failure rate due to soaring costs, Neurometric AI emerges with a $4M funding round and a new discipline: automated token engineering.

Americans spend hundreds annually on toilet paper, a product with a vast hidden environmental cost. A simple tech upgrade offers a payback in under a year.

Tarik Freitekh's new memoir details a life built on a phantom fortune, ending in prison. It's a stark lesson in the real cost of a fabricated reputation.

A former congressional candidate launches a podcast aiming to counter outrage. We analyze the strategic pivot and market viability of this new media venture.

A new AI platform for dental offices, Veo, is skipping the automation hype to focus on something radical: keeping humans in control. Is this the future?

Eightco Holdings offers a single stock for exposure to the future's giants. Is its concentrated bet on AI, crypto, and creators a stroke of genius?

Private equity giant Onex Partners acquires Canada's top fractional jet operator, AirSprint, in a strategic move to dominate the booming private aviation market.

Servier's new trial for a fatal pediatric epilepsy is more than a medical milestone; it's a strategic bet on high-risk, high-reward rare disease markets.

A Memphis family office, born from retail, is investing in AI's foundational layer. It's a sign of a larger shift as patient capital chases a new prize.

Greenland Mines charts a bold path for its Skaergaard project, but can it navigate the treacherous terrain of Arctic mining and financial instability?

Bluespring Wealth's acquisition of Element Wealth Advisors highlights a key industry trend: indie firms are seeking scale and tech to fuel client-first growth.

Koppers reports historic safety and emissions lows in its 2025 CSR, but the real story is its refreshed 2030 strategy—a plan for resilience and value.

A new partnership promises a less painful way to deliver cancer immunotherapy. We dive into the tech, the market, and why this is a key strategic play.

Lycia Therapeutics' oversubscribed $75M Series D validates its unique LYTAC platform, which aims to treat autoimmune diseases by destroying harmful proteins.

Automotive tech giant Visteon announced a massive share repurchase, delighting Wall Street. But in an industry demanding relentless innovation, is this the best use of capital?

As the GLP-1 market booms, Vivani Medical's new semaglutide implant promises a 'set-and-forget' solution to the adherence crisis plaguing weight-loss drugs.